a NEUROFARBA Department, Sezione di Scienze Farmaceutiche e Nutraceutiche , Università degli Studi di Firenze , Sesto Fiorentino (Florence) , Italy.
b School of Advanced Sciences , Center for Organic and Medicinal Chemistry , VIT University , Vellore , India.
J Enzyme Inhib Med Chem. 2018 Dec;33(1):1125-1136. doi: 10.1080/14756366.2018.1467901.
The synthesis of a new series of sulfamides incorporating ortho-, meta, and para-benzenesulfamide moieties is reported, which were investigated for the inhibition of two human (h) isoforms of the zinc enzyme carbonic anhydrase (CA, EC 4.2.1.1), hCA I and II, and two Vibrio cholerae enzymes, belonging to the α- and β-CA classes (VchCAα, VchCAβ). The compounds were prepared by using the "tail approach", aiming to overcome the scarcity of selective inhibition profiles associated to CA inhibitors belonging to the zinc binders. The built structure-activity relationship showed that the incorporation of benzhydryl piperazine tails on a phenyl sulfamide scaffold determines rather good efficacies against hCA I and VchCAα, with several compounds showing Ks < 100 nM. The activity was lower against hCA II and VchCAβ, probably due to the fact that the incorporated tails are quite bulky. The obtained evidences allow us to continue the investigations of different tails/zinc binding groups, with the purpose to increase the effectiveness/selectivity of such inhibitors against bacterial CAs from pathogens, affording thus potential new anti-infectives.
报告了一系列新的磺酰胺的合成,其中包含邻位、间位和对位苯磺酰胺部分,这些磺酰胺被研究用于抑制两种人源(h)锌酶碳酸酐酶(CA,EC 4.2.1.1)同工酶 hCA I 和 II,以及两种属于α-和β-CA 类的霍乱弧菌酶(VchCAα、VchCAβ)。这些化合物是通过使用“尾部方法”制备的,旨在克服与属于锌结合物的 CA 抑制剂相关的选择性抑制谱的缺乏。构建的结构-活性关系表明,将苯磺酰胺支架上的苄基哌嗪尾巴结合起来,可以很好地确定对 hCA I 和 VchCAα 的疗效,其中一些化合物的 Ks<100 nM。对 hCA II 和 VchCAβ 的活性较低,可能是因为结合的尾巴相当大。所获得的证据允许我们继续研究不同的尾巴/锌结合基团,目的是提高这些抑制剂对来自病原体的细菌 CA 的有效性/选择性,从而提供潜在的新型抗感染药物。